David Arkowitz insider trades
Open-market stock purchases and sales by David Arkowitz, Director at iBio, Inc, from SEC Form 4 filings since Feb 24, 2010.
Track record: 75% of 4 scored buys are up 5% or more since purchase, averaging +39%.
Companies traded
- IBIO iBio, Inc: 1 buy, last Oct 14, 2026
- KANT Kineta, Inc./de: other filings, last Jun 30, 2025
- KA Kineta, Inc./de: other filings, last Sep 4, 2024
- MCRB Seres Therapeutics, Inc: 2 sales, last Feb 16, 2024
- FSTX F-star Therapeutics, Inc: other filings, last Mar 8, 2023
- YMTX Yumanity Therapeutics, Inc: other filings, last Jun 2, 2021
- FLXN Flexion Therapeutics Inc: 4 buys, 5 sales, last May 10, 2021
- SBPH F-star Therapeutics, Inc: 2 buys, last Nov 19, 2020
- PTI Proteostasis Therapeutics, Inc: other filings, last Jun 29, 2020
- AMAG Amag Pharmaceuticals Inc: 3 buys, 3 sales, last May 31, 2011